CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


HP:0012418: HypoxemiaHPO

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (32)


Name (Synonyms) Correlation
drug1716 Oxygen Hood Wiki 0.23
drug1209 Inhaled budesonide and formoterol Wiki 0.23
drug1409 MK-5475 Wiki 0.23
drug2345 Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection Wiki 0.23
drug2346 Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation Wiki 0.23
drug1212 Inhaled placebo Wiki 0.23
drug1819 Pioglitazone Wiki 0.23
drug2552 Transfusion of COVID-19 convalescent plasma Wiki 0.23
drug1622 Non Extracorporeal Membrane Oxygenation Wiki 0.23
drug2219 Self-prone position recommendation Wiki 0.23
drug2615 Usual care Wiki 0.23
drug1210 Inhaled nitric oxide (iNO) Wiki 0.23
drug790 Double-Trunk Mask Wiki 0.23
drug2317 Standard interface Wiki 0.23
drug2344 Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation Wiki 0.23
drug1718 Oxygen gas Wiki 0.23
drug2639 VibroLUNG Wiki 0.23
drug812 ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY Wiki 0.23
drug2629 Vazegepant (BHV-3500) Wiki 0.23
drug917 FT516 Wiki 0.23
drug2347 Standard therapy recommended by the Ministry of Health of the Russian Federation. Wiki 0.23
drug1895 Predictive factors for clinical response in patients with COVID-19. Wiki 0.23
drug2280 Sodium Chloride 9mg/mL Wiki 0.23
drug813 ELMO PROJECT AT COVID-19: STUDY IN HUMANS Wiki 0.23
drug257 Awake proning Wiki 0.23
drug1609 Nitrogen gas Wiki 0.23
drug900 Extracorporeal Membrane Oxygenation Wiki 0.23
drug1303 L-ascorbic acid Wiki 0.16
drug788 Dornase Alfa Inhalation Solution [Pulmozyme] Wiki 0.16
drug1923 Prone positioning Wiki 0.13
drug1083 Hydrocortisone Wiki 0.11
drug1822 Placebo Wiki 0.03

Correlated MeSH Terms (11)


Name (Synonyms) Correlation
D000860 Hypoxia NIH 1.00
D012770 Shock, Cardiogenic NIH 0.23
D012769 Shock, NIH 0.09
D011665 Pulmonary Valve Insufficiency NIH 0.09
D012141 Respiratory Tract Infections NIH 0.05
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D011014 Pneumonia NIH 0.04
D012128 Respiratory Distress Syndrome, Adult NIH 0.04
D018352 Coronavirus Infections NIH 0.04
D012127 Respiratory Distress Syndrome, Newborn NIH 0.02
D007239 Infection NIH 0.01

Correlated HPO Terms (4)


Name (Synonyms) Correlation
HP:0030149 Cardiogenic shock HPO 0.23
HP:0010444 Pulmonary insufficiency HPO 0.09
HP:0011947 Respiratory tract infection HPO 0.05
HP:0002090 Pneumonia HPO 0.04

There are 19 clinical trials

Clinical Trials


1 Extracorporeal Membrane Oxygenation Support for Middle East Respiratory Syndrome Induced Respiratory Failure

A highly pathogenic human coronavirus causing respiratory disease emerged in Saudi Arabia in 2012. This viral infection termed Middle East respiratory syndrome coronavirus (MERS-CoV) is associated with high mortality rate in approximately 36% of reported patients. The World Health Organization (WHO) reported 1,374 laboratory-confirmed worldwide infections, including at least 490 related deaths, from September, 2012, to July 24, 2015.2 The higher incidence of MERS-CoV infections in Saudi Arabia may be related to multiple factors, including seasonality, increased proactive screening, poor infection control measures, low relative humidity, and high temperature. Infected patients with MERS-CoV usually have abnormal findings on chest radiography, ranging from subtle to extensive unilateral and bilateral abnormalities. MERS progresses rapidly to respiratory failure, in approximately 2/3 of infected patients, which has a high mortality rate, particularly in immunocompromised patients. Extracorporeal membrane oxygenation (ECMO) has emerged as a rescue therapy in patients with refractory hypoxemia during the H1N1 epidemic.The use of veno-venous (VV)-ECMO provides respiratory support for patients with respiratory failure, whereas the use of veno-arterial (VA)-ECMO could be helpful in those with cardiorespiratory failure.10 However, the survival rate of the infected patients with H1N1 who required the use of ECMO varies considerably among the Caucasian and Asian countries (90% survival in Sweden and 83% in the UK13 vs. 35% in Japan). This large discrepancy could be explained with lack of satisfactory equipment, therapeutic guidelines, training of staff, and effective systems allowing patient transfer to the dedicated ECMO centres. Guery and co-investigators described the use of ECMO in two French patients with cardiorespiratory failure secondary to MERS-CoV infection.This has been extended for treatment of refractory hypoxemic respiratory failure during the Saudi MERS-CoV outbreak.

NCT02627378 MERS-CoV Infection Refractory Hypoxemia Other: Extracorporeal Membrane Oxygenation Other: Non Extracorporeal Membrane Oxygenation
MeSH:Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: In-hospital mortality

Measure: Mortality rate

Time: For 2 months after admission to hospital

Secondary Outcomes

Description: Use of ribavirin or other anti-viral medications

Measure: Use of antiviral medications

Time: For 2 months after admission to hospital

Measure: Use of steroid medications

Time: For 2 months after admission to hospital

Measure: Use of interferons

Time: For 2 months after admission to hospital

Measure: Use of immunoglobulin

Time: For 2 months after admission to hospital

Description: Use of norepinephrine or vasopressin

Measure: Use of vasopressor medications

Time: For 2 months after admission to hospital

Description: Use of dobutamine, epinephrine, milirinone, levosimendan

Measure: Use of inotropic medications

Time: For 2 months after admission to hospital

Measure: Need for renal replacement therapy

Time: For 2 months after admission to hospital

Description: Changes in white and red blood cells and platelets counts

Measure: Changes in blood cell count

Time: For 2 months after admission to hospital

Description: Changes in serum creatinine and blood urea nitrogen evels

Measure: Changes in renal function tests

Time: For 2 months after admission to hospital

Description: Changes in arterial blood gases variables

Measure: Changes in arterial blood gases levels

Time: For 2 months after admission to hospital

Measure: Ratio of arterial oxygen tension (PaO2) to the fraction of inspired oxygen (FiO2) (PaO2/FiO2 ratio)

Time: For 2 months after admission to hospital

Measure: Use of alveolar recruitment technique

Time: For 2 months after admission to hospital

Measure: Use of prone ventilation

Time: For 2 months after admission to hospital

Measure: Use of neuromuscular blockades

Time: For 2 months after admission to hospital

Measure: Bacterial co-infection

Time: For 2 months after admission to hospital

Measure: Hospital length of stay

Time: For 2 months after admission to hospital

Measure: ICU length of stay

Time: For 2 months after admission to hospital

Measure: Extracorporeal membrane oxygenation support gas flow (liter/min)

Time: For 2 months after admission to hospital

Measure: Extracorporeal membrane oxygenation support blood flow (liter/min/m2)

Time: For 2 months after admission to hospital

Measure: Duration of Extracorporeal membrane oxygenation circulatory support

Time: For 2 months after admission to hospital

Other Outcomes

Measure: Number of participants with diabetes milletus on blood glucose test

Time: For 1 month before admission to hospital

Measure: Number of participants with pregnancy on pregnancy test

Time: For 9 months before admission to hospital

Measure: Number of participants with hypertension on blood pressure recordings

Time: For 1 month before admission to hospital

Measure: Number of participants with acute kidney injury on renal function tests

Time: For 1 month before admission to hospital

Measure: Number of participants with coronary artery disease on history, elctrocardiography and echocardiography

Time: For 1 month before admission to hospital

Measure: Number of participants with congestive heart failure on echocardiography

Time: For 1 month before admission to hospital

Measure: Number of participants with chronic kidney disease on renal function tests

Time: For 1 month before admission to hospital

Measure: Number of participants with liver cell disease on liver function tests

Time: For 1 month before admission to hospital

Measure: Number of participants with bronchial asthma on history and clinical examination

Time: For 1 month before admission to hospital

Measure: Number of participants with chronic obstructive pulmonary disease on history, chest radiography and pulmonary function tests

Time: For 1 month before admission to hospital

Measure: The presence of a predefined immunosuppression disease

Time: For 1 month before admission to hospital

2 ARrest RESpiraTory Failure From PNEUMONIA (ARREST PNEUMONIA)

This research study seeks to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.

NCT04193878 Pneumonia Hypoxemia Acute Respiratory Failure Drug: Inhaled budesonide and formoterol Drug: Inhaled placebo
MeSH:Pneumonia Respiratory Insufficiency Hypoxia
HPO:Hypoxemia Pneumonia

Primary Outcomes

Description: High flow nasal cannula (HFNC) and/or Noninvasive ventilation (NIV) use for greater than 36 hours OR Invasive mechanical ventilation for greater than 36 hours OR Death in a patient placed on respiratory support (HFNC, NIV, ventilator) who dies before 36 hours

Measure: Acute respiratory failure (ARF)

Time: within 7 days of randomization

Secondary Outcomes

Measure: Hospital length of stay

Time: within 60 days of randomization

Measure: Duration of need for supplemental oxygen

Time: within 60 days of randomization

Measure: Proportion of patients intubated for respiratory failure

Time: Within 7 days of randomization

3 Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study (ProCov)

The prone position consists of placing the patient on his or her stomach with the head on the side, during sessions lasting several hours a day and could help spontaneous ventilate the patient.

NCT04344106 Coronavirus Infection Oxygen Deficiency Procedure: Prone positioning
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: PaO2 improvement of more than 20% after one hour in prone position in spontaneously breathing non intubated COVID-19 patients.

Measure: Proportion of "responder" patients to prone position

Time: 1 hour

Secondary Outcomes

Description: PaO2 improvement of more than 20% at 6 to 12 hours from return to supine position.

Measure: proportion of "persistent responders" patients after prone position

Time: 1 day

Description: PaO2 at 1 hour from the start of prone position and at 6 to 12 hours afterreturn to supine position.

Measure: Evolution of PaO2

Time: 1 day

Description: Look for an association between the time spent in Prone positione and persistent responder or not;

Measure: Duration of prone positioning and PaO2 evolution

Time: 2 days

Description: proportion of patients improving their arterial saturation within 1 hour of Prone Position

Measure: Evolution of Spo2

Time: 1 hour

Description: evolution of the EVA scores for dyspnea at 1 hour from the start of the Prone Position and at 6 hours after the end of the Prone Position

Measure: EVA Dyspnea

Time: 1 day

Description: proportion of patients intolerant to prone position (Prone Position <1h);

Measure: Intolerance to prone positioning

Time: 1 day

Description: proportion of patients who can maintain prone position for more than 3 h.

Measure: Tolerance to prone positioning

Time: 1 day

4 Awake Prone Position for Early Hypoxemia in COVID-19

Prone positioning is a well studied and validated treatment for severe acute respiratory distress syndrome (ARDS), however there are no randomized studies on the use of prone positioning in the non-intubated patient. It is unknown if this intervention would be helpful in preventing further respiratory deterioration in terms of increasing supplemental oxygen requirements, endotracheal intubation, and ICU admission. The Awake Prone Position for Early hypoxemia in COVID-19 (APPEX-19) Study is a pragmatic adaptive randomized controlled unblinded trial. APPEX-19 randomizes non-ICU patients with COVID-19 or who are under evaluation for COVID-19 to lie in a prone position (i.e, with their stomach and chest facing down) or to usual care.

NCT04344587 COVID-19 Other: Self-prone position recommendation Other: Usual care
MeSH:Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: Change in respiratory status will be defined as:1) admission to the ICU and/or a 2) an increase in supplemental oxygen delivery (defined as an increase in oxygen delivery rate of ≥2 liter per minute compared to the oxygen delivery rate at the time of intervention or usual care text message that is sustained for ≥12 or more hours OR the switch to an oxygen delivery method that increases the level of supplemental oxygen.

Measure: Change in respiratory status

Time: up to 30 days

Secondary Outcomes

Description: Length of time in the prone position will be assessed from the smartphone survey and measured in categories of no time, up to 6 hours, 6 hours to 11 hours, 12 hours or more.

Measure: Length of time participant spends in the prone position

Time: up to 30 days

Description: Length of time in the supine/lying on back position will be assessed from the smartphone survey and measured in categories of no time, up to 6 hours, 6 hours to 11 hours, 12 hours or more.

Measure: Length of time participant spends in the supine position

Time: up to 30 days

Description: Length of time lying on side will be assessed from the smartphone survey and measured in categories of no time, up to 6 hours, 6 hours to 11 hours, 12 hours or more.

Measure: Length of time participant spends lying on side

Time: up to 30 days

Description: Length of time sitting up will be assessed from the smartphone survey and measured in categories of no time, up to 6 hours, 6 hours to 11 hours, 12 hours or more.

Measure: Length of time participant spends sitting up

Time: up to 30 days

Description: Length of time standing or walking will be assessed from the smartphone survey and measured in categories of no time, up to 6 hours, 6 hours to 11 hours, 12 hours or more.

Measure: Length of time participant spends standing or walking

Time: up to 30 days

Description: Dyspnea will be assessed by the modified Borg Dyspnea Score (10-point ordinal scale) from 1= nothing at all to 10= maximal. Higher scores indicate more dyspnea.

Measure: Dyspnea or difficult/labored breathing

Time: up to 30 days

Description: Discomfort with proning (4-point ordinal scale: very comfortable, somewhat comfortable, somewhat uncomfortable, very uncomfortable)

Measure: Discomfort with proning

Time: up to 30 days

Description: Total number of days hospitalized will be abstracted from the electronic medical record.

Measure: Length of hospital stay

Time: up to 30 days

Description: Invasive mechanical ventilation will be abstracted from the electronic medical record.

Measure: Invasive mechanical ventilation

Time: up to 30 days

Description: Loss of IV access as a consequence of turning in bed will be reported by participant using monitoring surveys

Measure: Loss of IV access as a consequence of turning in bed

Time: up to 30 days

Description: ARDS diagnosis will be abstracted from the electronic medical record

Measure: Acute respiratory distress syndrome (ARDS) diagnosis

Time: up to 30 days

Description: Hospital mortality will be abstracted from the electronic medical record

Measure: Hospital mortality

Time: up to 30 days

5 Impact of the Double-Trunk Mask on Oxygenation Titration in Patients With COVID-19

This study will investigate the impact of the Double-Trunk Mask (DTM) on the reduction of oxygen titration in patients with severe hypoxemia.

NCT04346420 COVID Hypoxemia Other: Standard interface Device: Double-Trunk Mask
MeSH:Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: The O2 output will be adjusted to maintain a SpO2 of 94% using both systems for administering O2. The O2 flow will be read from the position of the ball in flow meters.

Measure: Change in O2 output

Time: At baseline and 30 minutes after wearing both systems

Secondary Outcomes

Description: A Likert scale from 0 to 5 will be used to measure the subjective comfort of the patient while wearing the standard interface for administering O2 and/or the DTM

Measure: Comfort with the interfaces

Time: 30 minutes after wearing both systems

Description: Oxygen tension (PaO2) in mmHg will be analyzed from a sample taken from the arterial system

Measure: Changes in PaO2

Time: At baseline and 30 minutes after wearing DTM

Description: Carbon dioxide tension (PaCO2) in mmHg will be analyzed from a sample taken from the arterial system.

Measure: Changes in PaCO2

Time: At baseline and 30 minutes after wearing DTM

Description: Potential of Hydrogen (pH) will be analyzed from a sample taken from the arterial system.

Measure: Changes in pH

Time: At baseline and 30 minutes after wearing DTM

Description: Respiratory rate is measured during one minute by visual inspection.

Measure: Changes in respiratory rate

Time: At baseline and 30 minutes after wearing both systems

6 An Open Randomized Study of the Effectiveness of the Drug Dalargin for the Prevention and Treatment of Symptoms of Pulmonary Complications in Patients With Coronavirus Infection (SARS-COVID-19)

The purpose of the study is to evaluate an effectiveness of the drug Dalargin for the prevention and treatment of severe pulmonary complications symptoms associated with severe and critical coronavirus infection cases (SARS COVID19, expanded as Severe acute respiratory syndrome Cоrona Virus Disease 2019 ). Test drug that will be administered to patients are: - Dalargin, solution for inhalation administration, - Dalargin, solution for intravenous and intramuscular administration.

NCT04346693 Acute Respiratory Tract Infection Acute Respiratory Insufficiency Pneumonia Septic Shock Hypoxemia Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation. Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation Procedure: Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation
MeSH:Infection Respiratory Tract Infections Pneumonia Respiratory Insufficiency Pulmonary Valve Insufficiency Hypoxia
HPO:Hypoxemia Pneumonia Pulmonary insufficiency Respiratory tract infection

Primary Outcomes

Description: Estimated by Polymerase chain reaction (PCR)

Measure: The change of viral load in patients with SARS-COVID-19.

Time: Upon patient inclusion in the study, after 96 hours and on the 10day;

Description: Assessed through the entire patient participation in the study

Measure: The frequency of development of Acute Respiratory Distress Syndrome (ADRS)

Time: up to 10 days

Description: The number of days a patient is hospitalized

Measure: Duration of hospitalization

Time: up to 10 days

Description: Early mortality from all causes will be estimated

Measure: The frequency of early mortality

Time: up to 30 days

Description: Late mortality from all causes will be estimated

Measure: The frequency of late mortality

Time: up to 90 days

Description: Clinical status at the time of completion of participation in the study will be estimated based upon the following criteria: Death; Hospitalization is extended, on invasive mechanical ventilation of the lungs with extracorporeal membrane oxygenation; Hospitalization extended, on non-invasive ventilation; Hospitalization is extended, needs additional oxygen; Hospitalization is extended, additional oxygen is not required; Discharged.

Measure: Clinical status at the time of completion of participation in the study

Time: an average of 10 days

7 Low-dose Hydrocortisone in Patients With COVID-19 and Severe Hypoxia - the COVID STEROID Trial

We aim to assess the benefits and harms of low-dose hydrocortisone in patients with COVID-19 and severe hypoxia.

NCT04348305 Covid-19 Hypoxia Drug: Hydrocortisone Drug: Sodium Chloride 9mg/mL
MeSH:Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 28

Measure: Days alive without life support at day 28

Time: Day 28 after randomisation

Secondary Outcomes

Description: Death from all causes

Measure: All-cause mortality at day 28

Time: Day 28 after randomisation

Description: Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) from randomisation to day 90

Measure: Days alive without life support at day 90

Time: Day 90 after randomisation

Description: Death from all causes

Measure: All-cause mortality at day 90

Time: Day 90 after randomisation

Description: Defined as new episodes of septic shock, invasive fungal infection, clinically important GI bleeding or anaphylactic reaction

Measure: Number of participants with one or more serious adverse reactions

Time: Day 14 after randomisation

Description: Number of days alive and out of hospital not limited to the index admission

Measure: Days alive and out of hospital at day 90

Time: Day 90 after randomisation

Description: Death from all causes

Measure: All-cause mortality at 1 year after randomisation

Time: 1 year after randomisation

Description: Assessed by EQ-5D-5L

Measure: Health-related quality of life at 1 year

Time: 1 year after randomisation

Description: Assessed by EQ-VAS

Measure: Health-related quality of life at 1 year

Time: 1 year after randomisation

8 Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial

Previous research has shown that high dose intravenous vitamin C (HDIVC) may benefit patients with sepsis, acute lung injury (ALI), and the acute respiratory distress syndrome (ARDS). However, it is not known if early administration of HDIVC could prevent progression to ARDS. We hypothesize that HDIVC is safe and tolerable in Coronavirus disease 2019 (COVID-19) subjects given early or late in the disease course and may reduce the risk of respiratory failure requiring mechanical ventilation and development of ARDS along with reductions in supplemental oxygen demand and inflammatory markers.

NCT04357782 COVID-19 Hypoxia Drug: L-ascorbic acid
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: Occurrence of adverse events during study drug infusion

Measure: Incidence of adverse events

Time: Days 1-4

Description: Occurrence of serious adverse events during study drug infusion

Measure: Incidence of serious adverse reactions

Time: Days 1-4

Description: Occurrence of adverse reactions during study drug infusion

Measure: Incidence of adverse reactions

Time: Days 1-4

Secondary Outcomes

Description: Documented days free off mechanical ventilation the first 28 days post enrollment

Measure: Ventilator-free days

Time: Days 1-28

Description: Documented days free of ICU admission the first 28 days post enrollment

Measure: ICU-free days

Time: Days 1-28

Description: Documented days free of hospital admission the first 28 days post enrollment

Measure: Hospital-free days

Time: Days 1-28

Description: Incidence of mortality at 28 days by all causes

Measure: All-cause mortality

Time: Days 1-28

Description: SpO2 (% peripheral oxygenation saturation) will be divided by fraction of inspired oxygen (FiO2) at start of study infusion and compared with S/F ratio at end of study infusion

Measure: Change in S/F ratio during HDIVC infusion

Time: Days 1-4

Description: The difference in serum CRP during HDIVC infusion reported in mg/dL

Measure: C-reactive protein (CRP)

Time: Days 1-4

Description: The difference in LDH during HDIVC infusion will be reported in IU/L

Measure: Lactate dehydrogenase (LDH)

Time: Days 1-4

Description: The difference in D-dimer during HDIVC infusion will be reported in ug/mL

Measure: D-dimer

Time: Days 1-4

Description: The difference in lymphocyte count during HDIVC infusion will be reported in 10e3/uL

Measure: Lymphocyte count

Time: Days 1-4

Description: The NLR will be calculated by dividing the absolute neutrophil count (10e3/uL) over the absolute lymphocyte count (10e3/uL) and ratio compared with Day 1 versus Day 4

Measure: Neutrophil to Lymphocyte ratio (NLR)

Time: Days 1-4

Description: The difference in serum ferritin will be calculated from the start of HDIVC infusion to day 4 and reported as ng/mL

Measure: Serum Ferritin

Time: Days 1-4

9 A Single-site, Randomised, Controlled, Parallel Design, Open-label Investigation of an Approved Nebulised Recombinant Human DNase Enzyme (Dornase Alfa) to Reduce Hyperinflammation in Hospitalised Participants With COVID-19

An open-label, randomised, Best-Available-Care (BAC) and historic-controlled trial of nebulised dornase alfa [2.5 mg BID] for 7 days in participants with COVID-19 who are admitted to hospital and are at risk of ventilatory failure (the COVASE study). Controls will include a randomised arm to receive BAC, historic data from UCLH patients with COVID-19 and biobanked samples will be used to demonstrate an effect of dornase alfa. CRP will be measured to assess the effect of dornase alfa on inflammation. Clinical endpoints and biomarkers (e.g. d-dimer) will be used to assess the clinical response. Exploratory endpoints will explore the effects of dornase alfa on features of neutrophil extracellular traps (NETs).

NCT04359654 COVID19 Hypoxia Drug: Dornase Alfa Inhalation Solution [Pulmozyme]
MeSH:Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: Analysing stabilisation of C-reactive protein

Measure: Measuring the change in inflammation

Time: 7 days

Secondary Outcomes

Description: How many patients that are still alive

Measure: Number of patients that are alive at 28 days

Time: 28 days

Description: How many days on oxygen

Measure: Amount of days that patient requires oxygen

Time: 7 days

Description: Calculating index with Fi02, mean airways pressure and Pa02 via https://www.mdcalc.com/oxygenation-index#use-cases

Measure: Average oxygenation index

Time: 7 days

Description: How many days as an inpatient

Measure: Days patient admitted to hospital

Time: 7 days

Description: How many patients require mechanical ventilation

Measure: Percentage of patients that need mechanical ventilation

Time: 7 days

10 Study of FT516 Safety and Feasibility for the Treatment of Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients With Hypoxia

This is a Phase I study with the primary objective of identifying the maximum tolerated dose (MTD) of FT516 using 3 dose-escalation strategies (number of doses and cell dose) for the treatment of coronavirus disease 2019 (COVID-19). This study provides initial estimates of safety and efficacy based on stable respiratory function, as well as, determining the feasibility for full-scale studies designed both for efficacy and safety.

NCT04363346 COVID-19 Drug: FT516
MeSH:Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: An accelerated (fast-track) design will continue until first DLT is observed or the maximum Tolerated Dose (MTD) is determined. DLT is defined as any treatment emergent toxicity within 7 days after the last dose of FT516 meeting one of the following criteria based on CTCAE v5: Grade 3 or greater infusion related reaction following FT516 infusion Any new or worsening Grade 3 and any Grade 4 adverse events with the exception of the following known complications of COVID-19: Grade 3 gastrointestinal disorders (diarrhea) Grade 3 hepatic investigations (ALT increased, AST increased) Grade 3 leukopenia/lymphopenia Respiratory deterioration between the 1st dose and 7 days after the last dose of FT516 defined as the need for any type of assisted ventilation (invasive or non-invasive including BiPAP) or oxygen delivery device intended to deliver ≥60% FiO2 (including non-rebreather mask or >10L by simple facemask) to maintain an SpO2 >88%.

Measure: Number of participants with Dose Limiting Toxicity Events

Time: within 7 days after the last dose of FT516

Secondary Outcomes

Measure: The time in days from the 1st FT516 infusion to the elimination of viral shedding in nasal pharyngeal and stool samples

Time: 36 days

Measure: The time in days from the 1st FT516 infusion to discontinued need for supplemental oxygen

Time: 36 Days

Measure: The time in days from the 1st FT516 infusion to hospital discharge

Time: 36 Days

11 European/Euro-ELSO Survey on Adult and Neonatal/ Pediatric COVID Patients in ECMO

In the last 10 years, severe acute respiratory infection (SARI) was responsible of multiple outbreaks putting a strain on the public health worldwide. Indeed, SARI had a relevant role in the development of pandemic and epidemic with terrible consequences such as the 2009 H1N1 pandemic which led to more than 200.000 respiratory deaths globally. In late December 2019, in Wuhan, Hubei, China, a new respiratory syndrome emerged with clinical signs of viral pneumonia and person-to-person transmission. Tests showed the appearance of a novel coronavirus, namely the 2019 novel coronavirus (COVID-19). Two other strains, the severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have caused severe respiratory illnesses, sometimes fatal. In particular, the mortality rate associated with SARS-CoV and MERS-CoV, was of 10% and 37% respectively. Even though COVID-19 appeared from the first time in China, quickly it spread worldwide and cases have been described in other countries such as Thailand, Japan, South Korea, Germany, Italy, France, Iran, USA and many other countries. An early paper reported 41 patients with laboratory-confirmed COVID-19 infection in Wuhan. The median age of the patients was 49 years and mostly men (73%). Among those, 32% were admitted to the ICU because of the severe hypoxemia. The most associated comorbidities were diabetes (20%), hypertension (15%), and cardiovascular diseases (15%). On admission, 98% of the patients had bilateral multiple lobular and sub-segmental areas of consolidation. Importantly, acute respiratory distress syndrome (ARDS) developed in 29% of the patients, while acute cardiac injury in 12%, and secondary infection in 10%. Invasive mechanical ventilation was required in 10% of those patients, and two of these patients (5%) had refractory hypoxemia and received extracorporeal membrane oxygenation (ECMO). In a later retrospective report by Wang and collaborators, clinical characteristics of 138 patients with COVID-19 infection were described. ICU admission was required in 26.1% of the patients for acute respiratory distress syndrome (61.1%), arrhythmia (44.4%), and shock (30.6%). ECMO support was needed in 11% of the patients admitted to the ICU. During the period of follow-up, overall mortality was 4.3%. The use of ECMO in COVID-19 infection is increasing due to the high transmission rate of the infection and the respiratory-related mortality. Therefore, the investigators believe that ECMO in case of severe interstitial pneumonia caused by COVID could represent a valid solution in order to avoid lung injuries related to prolonged treatment with non-invasive and invasive mechanical ventilation. In addition, ECMO could have a role for the systemic complications such as septic and cardiogenic shock as well myocarditis scenarios. Potential clinical effects and outcomes of the ECMO support in the novel coronavirus pandemic will be recorded and analyzed in our project. The researchers hypothesize that a significant percentage of patients with COVID-19 infection will require the utilize of ECMO for refactory hypoxemia, cardiogenic shock or septic shock. This study seeks to prove this hypothesis by conducting an observational retrospective/prospective study of patients in the ICU who underwent ECMO support and describe clinical features, severity of pulmonary dysfunction and risk factors of COVID-patients who need ECMO support, the incidence of ECMO use, ECMO technical characteristics, duration of ECMO, complications and outcomes of COVID-patients requiring ECMO support.

NCT04366921 COVID SARS-CoV-2 ARDS, Human Refractory Hypoxemia Cardiogenic Shock Septic Shock Extracorporeal Membrane Oxygenation
MeSH:Respiratory Distress Syndrome, Adult Shock, Cardiogenic Shock Hypoxia
HPO:Cardiogenic shock Hypoxemia

Primary Outcomes

Description: age in years

Measure: Age

Time: at baseline

Description: male/female

Measure: Gender

Time: at baseline

Description: in kilograms

Measure: Weight

Time: at baseline

Description: in meters

Measure: Height

Time: at baseline

Description: weight and height combined to calculate BMI in kg/m^2

Measure: BMI

Time: at baseline

Description: Asthma y/n, cystic fibrosis y/n, chronic obstructive pulmonary disease y/n, pulmonary hypertension y/n, pulmonary fibrosis y/n, chronic restrictive lung disease y/n

Measure: Pre-existing pulmonary disease y/n

Time: at baseline

Description: diabetes mellitus y/n, chronic renal failure y/n, ischemic heart disease y/n, heart failure y/n, chronic liver failure y/n, neurological impairment y/n

Measure: Main co-morbidities y/n

Time: at baseline

Description: in dd-mm-yyyy or mm-dd-yyyy

Measure: Date of signs of COVID-19 infection

Time: at baseline or date of occurence

Description: in dd-mm-yyyy or mm-dd-yyyy

Measure: Date of positive swab

Time: at baseline or date of occurence

Description: in days

Measure: Pre-ECMO length of hospital stay

Time: at or during ECMO-implant

Description: in days

Measure: Pre-ECMO length of ICU stay

Time: at or during ECMO-implant

Description: in days

Measure: Pre-ECMO length of mechanical ventilation days

Time: at or during ECMO-implant

Description: y/n, what kind

Measure: Use of antibiotics

Time: up to 6 months

Description: y/n, what kind

Measure: Use of anti-viral treatment

Time: up to 6 months

Description: y/n, what kind (eg prone-position, recruitment manoeuvers, neuromuscular blockade etc)

Measure: Use of second line treatment

Time: up to 6 months

Description: respiratory or cardiac

Measure: Indications for ECMO-implant

Time: at ECMO-implant

Description: veno-venous, veno-arterial or veno-venoarterial

Measure: Type of ECMO-implant

Time: at ECMO-implant

Description: peripheral or central

Measure: Type of access

Time: at ECMO-implant

Description: in dd-mm-yyyy or mm-dd-yyyy

Measure: Date of ECMO implant

Time: at ECMO-implant

Description: l/min

Measure: ECMO blood flow rate

Time: from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months

Description: l/min

Measure: ECMO gas flow rate

Time: from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months

Description: y/n

Measure: ECMO configuration change

Time: up to 6 months

Description: in dd-mm-yyyy or mm-dd-yyyy

Measure: Date of ECMO configuration change

Time: up to 6 months

Description: veno-venous, veno-arterial, veno-venoarterial, other

Measure: New ECMO configuration

Time: up to 6 months

Description: right ventricular failure, left ventricular failure, refractory hypoxemia

Measure: Indications for ECMO configuration change

Time: up to 6 months

Description: settings of ventilator

Measure: Ventilator setting on ECMO

Time: from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months

Description: heparin, bivalirudin, nothing

Measure: Anticoagulation during ECMO

Time: from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months

Description: amount of ECMO circuit changes (1, 2, 3 etc.)

Measure: Frequency of ECMO circuit change

Time: up to 6 months

Description: Hemorrhagic, infection, other complications

Measure: ECMO complications

Time: up to 6 months

Description: y/n

Measure: ECMO Weaning

Time: from day of ECMO-implant for every 24 hours until date of weaning or death, up to 6 months

Description: y/n, date

Measure: ICU discharge

Time: from day of ICU-admission for every 24 hours until date of discharge or death, up to 6 months

Measure: Main cause of death

Time: 6 months

Description: Ward, another ICU, rehabilitation center, home

Measure: Type of discharge

Time: up to 6 months

Measure: Alive/deceased

Time: 6 months

12 Main Features and Ventilatory Management of Patients With ARDS Caused by COVID-19

Patients with the acute respiratory distress syndrome (ARDS) have markedly varied clinical presentations. Main characteristics of mechanically ventilated ARDS caused by COVID-19, and adherence to lung-protective ventilation strategies are not well known.

NCT04368975 Acute Respiratory Failure With Hypoxia
MeSH:Respiratory Insufficiency Hypoxia
HPO:Hypoxemia

Primary Outcomes

Measure: Discontinuation from mechanical ventilation

Time: 28 days

13 Randomized Controlled Trial Of A Delivered Continuously By Nasal Cannula For The Treatment Of Patients With COVID-19 And Mild To Moderate Hypoxemia Requiring Supplemental Oxygen

This randomized, controlled trial will assess the efficacy and safety of pulsed iNO in subjects with COVID-19 who are hospitalized and require supplemental oxygen.

NCT04398290 COVID-19 Hypoxemia Hypoxemic Respiratory Failure Drug: Inhaled nitric oxide (iNO) Drug: Nitrogen gas Drug: Oxygen gas
MeSH:Respiratory Insufficiency Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: As assessed per treating physician's discretion.

Measure: Incidence of treatment emergent adverse events

Time: Up to 14 days

Description: Incidence of hypoxemia and hypotension as assessed per treating physician's discretion.

Measure: Incidence of adverse events

Time: Up to 6 hours

Description: Incidence of increase to > 5% total methemoglobin as assessed by pulse oximetry.

Measure: Incidence of methemoglobinemia

Time: Up to 14 days

Secondary Outcomes

Description: Worsening respiratory status as defined by any one of the following: Implementation of High Flow Nasal Cannula (HFNC), non-rebreather mask, non-invasive ventilation, intubation and mechanical ventilation or need for intubation (in the event the patient is not intubated due to do not intubate (DNI) or do not resuscitate (DNR) status).

Measure: Number of participants with progression of respiratory failure

Time: Up to 14 days

Description: The number of days until hypoxemia is resolved as per treating physician assessment

Measure: Time until resolution of hypoxemia

Time: Up to 14 days

Description: Incidence of death during hospitalization and after discharge up to 28 days

Measure: Incidence of mortality

Time: Up to 28 days

Description: Number of days of hospitalization

Measure: Duration of hospitalization

Time: Up to 28 days

14 The Use of Oxygen Hoods as Compared to Conventional High-flow Oxygen Delivery Systems, the Effects on Oxygenation, Intubation and Mortality Rates, and Length of Hospitalization in Hypoxic Patients With COVID-19. A Prospective Controlled Cohort Study

To determine whether Oxygen hoods improve O2-saturation (SaO2), length of hospitalization, in-hospital intubation, and mortality rates in Covid-19 patients when compared to conventional high-flow oxygen delivery systems.

NCT04407260 COVID -19 Respiratory Failure Hypoxia Device: Oxygen Hood
MeSH:Respiratory Insufficiency Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: Continuous pulse oximetry monitoring

Measure: Oxygen saturation

Time: 3/6/2020 - 5/1/2020

Description: Intubation/mechanical Ventilation at any point during hospitalization.

Measure: In-hospital Intubation/Mechanical Ventilation

Time: 3/6/2020 - 5/1/2020

Description: In-hospital Mortality status

Measure: In-hospital Mortality

Time: 3/6/2020 - 5/1/2020

Description: Duration of hospitalization

Measure: Length of Hospitalization

Time: 3/6/2020 - 5/1/2020

15 Awake Proning in Patients With COVID-19-Induced Acute Hypoxemic Respiratory Failure

The purpose of this study is to retrospectively review clinical data to determine whether awake proning improves oxygenation in spontaneously breathing patients with COVID-19 severe hypoxemic respiratory failure.

NCT04408222 Oxygen Deficiency Coronavirus Infection Other: Awake proning
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Respiratory Insufficiency Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: SpO2 was measured by peripheral pulse oximetry.

Measure: Change in SpO2

Time: Before proning and 1 hour after initiation of the prone position

Secondary Outcomes

Description: The mean risk difference in intubation rates for patients with SpO2 ≥95% vs. <95% 1 hour after initiation of the prone position was assessed.

Measure: Mean Risk Difference in Intubation Rates

Time: Duration of hospitalization or up to 1 month from admission

16 A Study to Assess the Safety, Tolerability, and Pharmacodynamics of Multiple Dose MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia

The purpose of this study is to evaluate safety, tolerability, and pharmacodynamics of MK-5475 after administration of multiple doses to participants with COVID-19 pneumonia. The primary hypothesis is that MK-5475 when administered to participants with COVID-19 pneumonia and hypoxemia improves arterial oxygenation as measured by the ratio of blood oxygen saturation to fraction of inspired oxygen (SpO2/FiO2 ratio) compared to placebo.

NCT04425733 Coronavirus Disease 2019 (COVID-19) Pneumonia Hypoxemia Drug: MK-5475 Drug: Placebo
MeSH:Pneumonia Hypoxia
HPO:Hypoxemia Pneumonia

Primary Outcomes

Description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.

Measure: Number of Participants Who Experience an Adverse Event (AE)

Time: Up to ~Day 21

Description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study drug due to an AE will be reported.

Measure: Number of Participants Who Discontinued Study Drug Due to an Adverse Event (AE)

Time: Up to ~Day 7

Description: The SpO2/FiO2 ratio is a measure of arterial oxygenation. Noninvasive pulse oximetry will be used to obtain the SpO2/FiO2 ratio. The TWA0-24hrs will be calculated as the area under the curve from 0 to 24 hours post-dose on Day 1 divided by the length of time (24 hrs). Baseline is the Day 1 pre-dose measurement and assessments will be conducted pre-dose and at multiple time points post-dose on Day 1 to determine change from baseline in TWA0-24hrs for SpO2/FiO2 on Day 1.

Measure: Change From Baseline to Day 1 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2)

Time: Baseline, Day 1 (pre-dose and 2, 6, 12, 18, 24 hours post-dose)

Description: The SpO2/FiO2 ratio is a measure of arterial oxygenation. Noninvasive pulse oximetry will be used to obtain the SpO2/FiO2 ratio. The TWA0-24hrs will be calculated as the area under the curve from 0 to 24 hours on Day 2 divided by the length of time (24 hrs). Baseline is the Day 1 pre-dose measurement and assessments will be conducted pre-dose and at multiple time points post-dose on Day 2 to determine change from baseline in TWA0-24hrs for SpO2/FiO2 on Day 2.

Measure: Change From Baseline to Day 2 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2)

Time: Baseline, Day 2 (pre-dose and 2, 6, 12, 18, 24 hours post-dose)

Description: The SpO2/FiO2 ratio is a measure of arterial oxygenation. Noninvasive pulse oximetry will be used to obtain the SpO2/FiO2 ratio. The TWA0-24hrs will be calculated as the area under the curve from 0 to 24 hours on Day 3 divided by the length of time (24 hrs). Baseline is the Day 1 pre-dose measurement and assessments will be conducted pre-dose and at multiple time points post-dose on Day 3 to determine change from baseline in TWA0-24hrs for SpO2/FiO2 on Day 3.

Measure: Change From Baseline to Day 3 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2)

Time: Baseline, Day 3 (pre-dose and 2, 6, 12, 18, 24 hours post-dose)

Description: The SpO2/FiO2 ratio is a measure of arterial oxygenation. Noninvasive pulse oximetry will be used to obtain the SpO2/FiO2 ratio. The TWA0-24hrs will be calculated as the area under the curve from 0 to 24 hours on Day 4 divided by the length of time (24 hrs). Baseline is the Day 1 pre-dose measurement and assessments will be conducted pre-dose and at multiple time points post-dose on Day 4 to determine change from baseline in TWA0-24hrs for SpO2/FiO2 on Day 4.

Measure: Change From Baseline to Day 4 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2)

Time: Baseline, Day 4 (pre-dose and 2, 6, 12, 18, 24 hours post-dose)

Description: The SpO2/FiO2 ratio is a measure of arterial oxygenation. Noninvasive pulse oximetry will be used to obtain the SpO2/FiO2 ratio. The TWA0-24hrs will be calculated as the area under the curve from 0 to 24 hours on Day 5 divided by the length of time (24 hrs). Baseline is the Day 1 pre-dose measurement and assessments will be conducted pre-dose and at multiple time points post-dose on Day 5 to determine change from baseline in TWA0-24hrs for SpO2/FiO2 on Day 5.

Measure: Change From Baseline to Day 5 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2)

Time: Baseline, Day 5 (pre-dose and 2, 6, 12, 18, 24 hours post-dose)

Description: The SpO2/FiO2 ratio is a measure of arterial oxygenation. Noninvasive pulse oximetry will be used to obtain the SpO2/FiO2 ratio. The TWA0-24hrs will be calculated as the area under the curve from 0 to 24 hours on Day 6 divided by the length of time (24 hrs). Baseline is the Day 1 pre-dose measurement and assessments will be conducted pre-dose and at multiple time points post-dose on Day 6 to determine change from baseline in TWA0-24hrs for SpO2/FiO2 on Day 6.

Measure: Change From Baseline to Day 6 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2)

Time: Baseline, Day 6 (pre-dose and 2, 6, 12, 18, 24 hours post-dose)

Description: The SpO2/FiO2 ratio is a measure of arterial oxygenation. Noninvasive pulse oximetry will be used to obtain the SpO2/FiO2 ratio. The TWA0-24hrs will be calculated as the area under the curve from 0 to 24 hours on Day 7 divided by the length of time (24 hrs). Baseline is the Day 1 pre-dose measurement and assessments will be conducted pre-dose and at multiple time points post-dose on Day 7 to determine change from baseline in TWA0-24hrs for SpO2/FiO2 on Day 7.

Measure: Change From Baseline to Day 7 in the Time-weighted Average from 0 through 24 hours (TWA0-24hrs) for the Ratio of Blood Oxygen Saturation to the Fraction of Inspired Oxygen (SpO2/FiO2)

Time: Baseline, Day 7 (pre-dose and 2, 6, 12, 18, 24 hours post-dose)

17 Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19

Vibroacoustic pulmonary therapy in patients with COVID19 is believed to have a positive effect on oxygen status and a decrease in the duration of respiratory failure

NCT04435353 Respiratory Distress Syndrome Hypoxemia Device: VibroLUNG
MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Respiratory Insufficiency Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: Regression of respiratory failure under the influence of vibroacoustic therapy

Measure: Recovery respiratory fail

Time: 5-7 days

18 Elmo Respiratory Support Project for Patients With Hypoxemic Respiratory Insufficiency in Covid-19: Proof Of Concept and Usability

The number of COVID-19 cases has been growing exponentially, so that the industrialized economies are facing a significant shortage in the number of ventilators available to meet the demands imposed by the disease. Noninvasive ventilatory support can be valuable for certain patients, avoiding tracheal intubation and its complications. However, non-invasive techniques have a high potential to generate aerosols during their implementation, especially when masks are used in which it is virtually impossible to completely prevent air leakage and the dispersion of aerosols with viral particles. In this context, a helmet-like interface system with complete sealing and respiratory isolation of the patient's head can allow the application of ventilatory support without intubation and with safety and comfort for healthcare professionals and patients. This type of device is not accessible in Brazil, nor is it available for immediate import, requiring the development of a national product. Meanwhile, a task force under the coordination of the School of Public Health (ESP) and Fundação Cearense de Apoio à Pesquisa (FUNCAP), with support from SENAI / FIEC and the Federal Universities of Ceará (UFC) and the University of Fortaleza (UNIFOR) advanced in the development of a prototype and accessory system capable of providing airway pressurization through a helmet-type interface, which was called the Elmo System.

NCT04470258 COVID-19 Respiratory Failure With Hypoxia Other: ELMO PROJECT AT COVID-19: STUDY IN HUMANS Device: ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY
MeSH:Respiratory Insufficiency Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: Usability test with the description of the identified problems of the main basic skills necessary for the correct handling of the non-invasive respiratory device (ELMO), through realistic simulations, severity scale and usability.

Measure: Usability tests of the Elmo system using Euristic usability principles

Time: One week after all tests

Description: To evaluate the effectiveness of the Elmo system in the supportive treatment of patients with hypoxemic respiratory failure caused by COVID-19 through peripheral oxygen saturation (%) before, during and after the application of Elmo.

Measure: Evaluation of the effectiveness of the ELMO system using physiological parameters

Time: One week after all tests

Secondary Outcomes

Description: To evaluate the effectiveness of the Elmo system in the supportive treatment of patients with hypoxemic respiratory failure caused by COVID-19 through respiratory rate (irpm) before, during and after the application of Elmo.

Measure: Evaluation of the effectiveness of the ELMO system using physiological parameters

Time: One week after all tests

Description: To evaluate the effectiveness of the Elmo system in the supportive treatment of patients with hypoxemic respiratory failure caused by COVID-19 through heart rate before, during and after the application of Elmo.

Measure: Evaluation of the effectiveness of the ELMO system using physiological parameters

Time: One week after all tests

Description: To evaluate the effectiveness of the Elmo system in the supportive treatment of patients with hypoxemic respiratory failure caused by COVID-19 through blood pressure before, during and after the application of Elmo.

Measure: Evaluation of the effectiveness of the ELMO system using physiological parameters

Time: One week after all tests

Description: To evaluate the effectiveness of the Elmo system in the supportive treatment of patients with hypoxemic respiratory failure caused by COVID-19 through CO2 measurement at the end of exhalation (mmHg) before, during and after the application of Elmo.

Measure: Evaluation of the effectiveness of the ELMO system using physiological parameters

Time: One week after all tests

19 GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study

Pioglitazone is an approved anti-hyperglycemic medication and is thought to have anti-inflammatory properties. This study seeks to gather safety and tolerability data related to pioglitazone when given to patients who require hospital admission for confirmed positive COVID-19 infections with elevated blood sugar levels as compared to patients who did not receive pioglitazone during their hospitalization for COVID-19.

NCT04473274 Coronavirus Infection Diabetes Drug: Pioglitazone
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Hypoxia
HPO:Hypoxemia

Primary Outcomes

Description: Number and type of adverse events

Measure: Adverse events outcomes without attribution

Time: Baseline, until 30 days after last dose

Description: Number and type of adverse events

Measure: Adverse events attributable

Time: Baseline, until 30 days after last dose

Secondary Outcomes

Description: Disease severity as measured by 7 point ordinal scale

Measure: Clinical improvement

Time: Baseline, until 30 days after last dose

Description: Type of oxygen support treatment

Measure: Levels of treatment

Time: Baseline, until 30 days after last dose

Description: Change from Baseline of d-Dimer

Measure: d-Dimer

Time: Baseline, until 30 days after last dose

Description: Change from Baseline of CRP

Measure: C Reactive Protein

Time: Baseline, until 30 days after last dose

Description: Change from Baseline of Ferritin

Measure: Ferritin

Time: Baseline, until 30 days after last dose

Description: Change from Baseline of Lactate dehydrogenase

Measure: Lactate dehydrogenase

Time: Baseline, until 30 days after last dose

Description: Change from Baseline of A1c

Measure: A1c

Time: Baseline, until 30 days after last dose


HPO Nodes